IL2 and lung cancer: All the mice cured by vvDD-IL-2, vvDD-IL-2-FG, and vvDD-IL-2-RG treatment rejected a subcutaneous MC38 re-challenge (Supplementary Fig. 6a), but not an irrelevant tumour control Lewis lung cancer challenge (Supplementary Fig. 6b), which suggests that a systemic tumour-specific antitumour immune response was elicited.